Last mentioned: Feb 28, 2026
Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3%, selling 85,000 shares during the third quarter. Despite the divestment, the $15.45 million holding remains a core 5.0% of the firm's portfolio, signaling continued confidence in the ophthalmic specialist's pipeline.
Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3% during the third quarter, selling 85,000 shares. Despite the reduction, the firm maintains a high-conviction $15.45 million stake, representing 5% of its total investment portfolio.
Essex Woodlands Management Inc. reduced its position in EyePoint Pharmaceuticals by 7.3% in the third quarter, while maintaining a significant $15.45 million stake. The move reflects a strategic rebalancing as EyePoint advances its late-stage ophthalmic pipeline, particularly its DURAVYU™ platform.